This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DeFriend, D. J. Articles by Wakeling, A. E. Search for Related Content PubMed PubMed Citation Articles by DeFriend, D. J. Articles by Wakeling, A. E.

Investigation of a New Pure Antiestrogen (ICI 182780) in Women with Primary Breast Cancer¹

Department of Surgery [D. J. D., R. E. M., N. J. B.], Medical Oncology [A. H.], and Tumour Biochemistry [E. A.], Withington and Christie Hospitals Manchester, UK; Department of Surgery, The City Hospital, Nottingham, UK [R. W. B., J. F. R.]; Tenovus Institute for Cancer Research, Cardiff, UK [R. I. N.]; Department of Surgery [C. S.,M. B.] and Biochemistry [M. D.], Royal Marsden Hospital, London, UK; and Zeneca Pharmaceuticals, Macclesfield, UK [P. W., F. S., A. E. W.]

² To whom requests for reprints should be addressed, at Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, UK.

We have conducted a clinical trial of a novel pure antiestrogen, 7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]estra-1,3,5,(10)-triene-3,17β-diol (ICI 182780), to assess its tolerance, pharmacoldnetics, and short term biological effects in women with primary breast cancer. Fifty-six patients were randomized to either a control group (n = 19), in which they received no preoperative treatment, or a treatment group (n = 37), in which they received daily i.m. injections of ICI 182780 at doses of 6 mg (n = 21) or 18 mg (n = 16) for 7 days prior to primary breast surgery. Serum drug concentrations, gonadotropin levels, and sex hormone-binding globulin levels were measured during the study period by radioimmunoassay. Expression of estrogen receptors (ER), progesterone receptors, the estrogen-induced protein pS2, and the cell proliferation-related antigen Ki67 was determined immunocytochemically in pre- and poststudy tumor samples.

Treatment with ICI 182780 caused no serious drug-related adverse events and had no effect on serum gonadotropin or sex hormone-binding globulin levels. Minor adverse events occurred in 5 patients receiving the 6-mg dose and 3 patients receiving the 18-mg dose. The serum concentration of ICI 182780 was dose dependent but showed variation between individuals. There was evidence of an approximately 3-fold drug accumulation over the short treatment period but steady state levels were not reached by the end of the 7 days. In patients with ER-positive tumors, treatment with ICI 182780 was associated with significant reductions in the tumor expression of ER (median ER index, 0.72 before versus 0.02 after treatment; P < 0.001), progesterone receptor (median progesterone receptor index, 0.50 before versus 0.01 after treatment; P < 0.05), and Ki67 (median Ki67 labeling index, 3.2 before versus 1.1 after treatment; P < 0.05). Treatment with ICI 182780 also resulted in a significant reduction in pS2 expression (P < 0.05) but this appeared unrelated to tumor ER status.

In conclusion, ICI 182780 was well tolerated after short term administration and produced demonstrable antiestrogenic effects in human breast tumors in vivo, without showing evidence of agonist activity. These properties identify ICI 182780 as a candidate agent with which to evaluate whether a pure estrogen antagonist offers any additional benefit in the treatment of human breast cancer over conventional nonsteroidal antiestrogens, typified by tamoxifen, which exhibit variable degrees of agonist activity.

¹ Supported by financial assistance from Zeneca Pharmaceuticals (Macclesfield, UK).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/ 9/93. Accepted 11/10/93.

This article has been cited by other articles:

				S. Chia, W. Gradishar, L. Mauriac, J. Bines, F. Amant, M. Federico, L. Fein, G. Romieu, A. Buzdar, J. F.R. Robertson, et al. Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor-Positive, Advanced Breast Cancer: Results From EFECT J. Clin. Oncol., April 1, 2008; 26(10): 1664 - 1670. [Abstract] [Full Text] [PDF]

				M. Guix, N. de Matos Granja, I. Meszoely, T. B. Adkins, B. M. Wieman, K. E. Frierson, V. Sanchez, M. E. Sanders, A. M. Grau, I. A. Mayer, et al. Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor-Positive Breast Cancers J. Clin. Oncol., February 20, 2008; 26(6): 897 - 906. [Abstract] [Full Text] [PDF]

				H. S. Rugo The breast cancer continuum in hormone-receptor positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors Ann. Onc., January 1, 2008; 19(1): 16 - 27. [Abstract] [Full Text] [PDF]

				M. Dowsett and I. E. Smith Response: Re: Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer J Natl Cancer Inst, July 4, 2007; 99(13): 1053 - 1054. [Full Text] [PDF]

				J. F. R. Robertson Fulvestrant (Faslodex(R)) How to Make a Good Drug Better Oncologist, July 1, 2007; 12(7): 774 - 784. [Abstract] [Full Text] [PDF]

				J. Bowe, X. F. Li, J. Kinsey-Jones, A. Heyerick, S. Brain, S. Milligan, and K. O'Byrne The hop phytoestrogen, 8-prenylnaringenin, reverses the ovariectomy-induced rise in skin temperature in an animal model of menopausal hot flushes. J. Endocrinol., November 1, 2006; 191(2): 399 - 405. [Abstract] [Full Text] [PDF]

				A. Howell Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 689 - 706. [Abstract] [Full Text] [PDF]

				R. J. Pietras Biologic Basis of Sequential and Combination Therapies for Hormone-Responsive Breast Cancer Oncologist, July 1, 2006; 11(7): 704 - 717. [Abstract] [Full Text] [PDF]

				N. Andersson, U. Islander, E. Egecioglu, E. Lof, C. Swanson, S. Moverare-Skrtic, K. Sjogren, M. K Lindberg, H. Carlsten, and C. Ohlsson Investigation of central versus peripheral effects of estradiol in ovariectomized mice J. Endocrinol., November 1, 2005; 187(2): 303 - 309. [Abstract] [Full Text] [PDF]

				A. Urruticoechea, I. E. Smith, and M. Dowsett Proliferation Marker Ki-67 in Early Breast Cancer J. Clin. Oncol., October 1, 2005; 23(28): 7212 - 7220. [Abstract] [Full Text] [PDF]

				C J Fabian, B F Kimler, M S Mayo, and S A Khan Breast-tissue sampling for risk assessment and prevention Endocr. Relat. Cancer, June 1, 2005; 12(2): 185 - 213. [Abstract] [Full Text] [PDF]

				J. W. Wright, R. L. Stouffer, and K. D. Rodland High-Dose Estrogen and Clinical Selective Estrogen Receptor Modulators Induce Growth Arrest, p21, and p53 in Primate Ovarian Surface Epithelial Cells J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3688 - 3695. [Abstract] [Full Text] [PDF]

				W. J. Gradishar Tamoxifen--What Next? Oncologist, July 1, 2004; 9(4): 378 - 384. [Abstract] [Full Text] [PDF]

				V. Marsaud, A. Gougelet, S. Maillard, and J.-M. Renoir Various Phosphorylation Pathways, Depending on Agonist and Antagonist Binding to Endogenous Estrogen Receptor {alpha} (ER{alpha}), Differentially Affect ER{alpha} Extractability, Proteasome-Mediated Stability, and Transcriptional Activity in Human Breast Cancer Cells Mol. Endocrinol., October 1, 2003; 17(10): 2013 - 2027. [Abstract] [Full Text] [PDF]

				J. S. Carroll, D. K. Lynch, A. Swarbrick, J.-M. Renoir, B. Sarcevic, R. J. Daly, E. A. Musgrove, and R. L. Sutherland p27Kip1 Induces Quiescence and Growth Factor Insensitivity in Tamoxifen-treated Breast Cancer Cells Cancer Res., August 1, 2003; 63(15): 4322 - 4326. [Abstract] [Full Text] [PDF]

				K. E. Calhoun, R. F. Pommier, P. Muller, W. S. Fletcher, and S. Toth-Fejel Dehydroepiandrosterone Sulfate Causes Proliferation of Estrogen Receptor-Positive Breast Cancer Cells Despite Treatment With Fulvestrant Arch Surg, August 1, 2003; 138(8): 879 - 883. [Abstract] [Full Text] [PDF]

				M. Dowsett Preoperative Models to Evaluate Endocrine Strategies for Breast Cancer Clin. Cancer Res., January 1, 2003; 9(1): 502s - 510s. [Abstract] [Full Text]

				C. Harper-Wynne, G. Ross, N. Sacks, J. Salter, N. Nasiri, J. Iqbal, R. A'Hern, and M. Dowsett Effects of the Aromatase Inhibitor Letrozole on Normal Breast Epithelial Cell Proliferation and Metabolic Indices in Postmenopausal Women: A Pilot Study for Breast Cancer Prevention Cancer Epidemiol. Biomarkers Prev., July 1, 2002; 11(7): 614 - 621. [Abstract] [Full Text] [PDF]

				C. L. Harper-Wynne, N. P.M. Sacks, K. Shenton, F. A. MacNeill, P. Sauven, I. J. Laidlaw, Z. Rayter, S. Miall, A. Howes, J. Salter, et al. Comparison of the Systemic and Intratumoral Effects of Tamoxifen and the Aromatase Inhibitor Vorozole in Postmenopausal Patients With Primary Breast Cancer J. Clin. Oncol., February 15, 2002; 20(4): 1026 - 1035. [Abstract] [Full Text] [PDF]

				M. Dowsett, N. J. Bundred, A. Decensi, R. C. Sainsbury, Y. Lu, M. J. Hills, F. J. Cohen, P. Veronesi, M. E. R. O'Brien, T. Scott, et al. Effect of Raloxifene on Breast Cancer Cell Ki67 and Apoptosis: A Double-Blind, Placebo-controlled, Randomized Clinical Trial in Postmenopausal Patients Cancer Epidemiol. Biomarkers Prev., September 1, 2001; 10(9): 961 - 966. [Abstract] [Full Text] [PDF]

				J. F. Robertson, R. I. Nicholson, N. J. Bundred, E. Anderson, Z. Rayter, M. Dowsett, J. N. Fox, J. M. W. Gee, A. Webster, A. E. Wakeling, et al. Comparison of the Short-Term Biological Effects of 7{alpha}-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17{beta}-diol (Faslodex) versus Tamoxifen in Postmenopausal Women with Primary Breast Cancer Cancer Res., September 1, 2001; 61(18): 6739 - 6746. [Abstract] [Full Text] [PDF]

				T. A. Parker, S. Afshar, J. P. Kinsella, T. R. Grover, S. Gebb, M. Geraci, P. W. Shaul, C. M. T. Cryer, and S. H. Abman Effects of chronic estrogen-receptor blockade on ovine perinatal pulmonary circulation Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1005 - H1014. [Abstract] [Full Text] [PDF]

				R. A. McClelland, D. Barrow, T.-A. Madden, C. M. Dutkowski, J. Pamment, J. M. Knowlden, J. M. W. Gee, and R. I. Nicholson Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex) Endocrinology, July 1, 2001; 142(7): 2776 - 2788. [Abstract] [Full Text] [PDF]

				A. Gandhi, P. A. Holland, W. F. Knox, C. S. Potten, and N. J. Bundred Effects of a Pure Antiestrogen on Apoptosis and Proliferation within Human Breast Ductal Carcinoma in Situ Cancer Res., August 1, 2000; 60(15): 4284 - 4288. [Abstract] [Full Text]

				R. E. Favoni and A. De Cupis The Role of Polypeptide Growth Factors in Human Carcinomas: New Targets for a Novel Pharmacological Approach Pharmacol. Rev., June 1, 2000; 52(2): 179 - 206. [Abstract] [Full Text] [PDF]

				M. Dowsett, J. M. Dixon, K. Horgan, J. Salter, M. Hills, and E. Harvey Antiproliferative Effects of Idoxifene in a Placebo-controlled Trial in Primary Human Breast Cancer Clin. Cancer Res., June 1, 2000; 6(6): 2260 - 2267. [Abstract] [Full Text]

				C. A. Molloy, F. E. B. May, and B. R. Westley Insulin Receptor Substrate-1 Expression Is Regulated by Estrogen in the MCF-7 Human Breast Cancer Cell Line J. Biol. Chem., April 21, 2000; 275(17): 12565 - 12571. [Abstract] [Full Text] [PDF]

				Z. Nawaz, G. M. Stancel, and S. M. Hyder The Pure Antiestrogen ICI 182,780 Inhibits Progestin-induced Transcription Cancer Res., January 1, 1999; 59(2): 372 - 376. [Abstract] [Full Text] [PDF]

				T. Ördög, J. R. Goldsmith, M.-D. Chen, M. A. Connaughton, J. Hotchkiss, and E. Knobil On the Mechanism of the Positive Feedback Action of Estradiol on Luteinizing Hormone Secretion in the Rhesus Monkey J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 4047 - 4053. [Abstract] [Full Text]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]

				C. Martel, C. Labrie, A. Belanger, S. Gauthier, Y. Merand, X. Li, L. Provencher, B. Candas, and F. Labrie Comparison of the Effects of the New Orally Active Antiestrogen EM-800 with ICI 182 780 and Toremifene on Estrogen-Sensitive Parameters in the Ovariectomized Mouse Endocrinology, May 1, 1998; 139(5): 2486 - 2492. [Abstract] [Full Text] [PDF]

				D. O. Ruehlmann, J. R. Steinert, M. A. Valverde, R. Jacob, and G. E. Mann Environmental estrogenic pollutants induce acute vascular relaxation by inhibiting L-type Ca2+ channels in smooth muscle cells FASEB J, May 1, 1998; 12(7): 613 - 619. [Abstract] [Full Text]

				K. Yao and V. C. Jordan Questions about Tamoxifen and the Future Use of Antiestrogens Oncologist, April 1, 1998; 3(2): 104 - 110. [Abstract] [Full Text]

				A. Tremblay, G. B. Tremblay, C. Labrie, F. Labrie, and V. Giguere EM-800, a Novel Antiestrogen, Acts as a Pure Antagonist of the Transcriptional Functions of Estrogen Receptors {alpha} and {beta} Endocrinology, January 1, 1998; 139(1): 111 - 118. [Abstract] [Full Text] [PDF]

				J. S. Carroll, O. W. J. Prall, E. A. Musgrove, and R. L. Sutherland A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence J. Biol. Chem., December 1, 2000; 275(49): 38221 - 38229. [Abstract] [Full Text] [PDF]